SRP3010
BCMA human
recombinant, expressed in E. coli, ≥98% (SDS-PAGE), ≥98% (HPLC), suitable for cell culture
Synonym(s):
B-Cell Maturation Antigen, BCM, TNFRSF17
Sign Into View Organizational & Contract Pricing
All Photos(1)
About This Item
UNSPSC Code:
12352202
NACRES:
NA.32
Recommended Products
biological source
human
recombinant
expressed in E. coli
Assay
≥98% (HPLC)
≥98% (SDS-PAGE)
form
lyophilized
mol wt
5.3 kDa
packaging
pkg of 20 μg
technique(s)
cell culture | mammalian: suitable
impurities
<0.1 EU/μg endotoxin, tested
UniProt accession no.
shipped in
wet ice
storage temp.
−20°C
Gene Information
human ... TNFRSF17(608)
General description
B-cell maturation antigen (BCMA) or tumor necrosis factor receptor superfamily member 17(TNFRSF17), a member of the tumor necrosis factor (TNF) receptor superfamily, binds to B-cell–activating factor (BAFF) and a proliferation-inducing ligand (APRIL). BCMA is expressed on mature B-cells and other B-cell lines. The human BCMA gene codes for a 184 amino acid type I transmembrane protein, which contains a 54 amino acid extracellular domain, a 23 amino acid transmembrane domain, and a 107 amino acid cytoplasmic domain. Recombinant soluble human BCMA is a 50 amino acid polypeptide (5.3kDa) comprising the TNFR homologous region of the BCMA protein.
Biochem/physiol Actions
B-cell maturation antigen (BCMA) or tumor necrosis factor receptor superfamily member 17 (TNFRSF17) plays an important role in B cell development, function and regulation. BCMA also has the capability to activate nuclear factor-κB (NF-κB), janus kinase (JNK) and mitogen activated protein kinases (MAPKs). The protein is expressed in certain cancers like glioblastoma, chronic lymphocytic leukemia, Hodgkin lymphoma and multiple myeloma. It has a role in the maintenance of survival of long-lived plasma cells in bone marrow.
Sequence
AGQCSQNEYF DSLLHACIPC QLRCSSNTPP LTCQRYCNAS VTNSVKGTNA
Physical form
Lyophilized with no additives.
Reconstitution
Centrifuge the vial prior to opening. Reconstitute in water to a concentration of 0.1-1.0 mg/ml. Do not vortex. This solution can be stored at 2-8°C for up to 1 week. For extended storage, it is recommended to further dilute in a buffer containing a carrier protein (example 0.1% BSA) and store in working aliquots at -20°C to -80°C
Storage Class Code
11 - Combustible Solids
WGK
WGK 3
Certificates of Analysis (COA)
Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
B cell maturation antigen, the receptor for a proliferation-inducing ligand and B cell-activating factor of the TNF family, induces antigen presentation in B cells.
Yang M
Journal of Immunology, 175(5), 2814-2824 (2005)
P Rennert et al.
The Journal of experimental medicine, 192(11), 1677-1684 (2000-12-06)
A proliferation-inducing ligand (APRIL) is a ligand of the tumor necrosis factor (TNF) family that stimulates tumor cell growth in vitro and in vivo. Expression of APRIL is highly upregulated in many tumors including colon and prostate carcinomas. Here we
Christine M Coquery et al.
Critical reviews in immunology, 32(4), 287-305 (2012-12-15)
B cell maturation antigen (BCMA) is a tumor necrosis family receptor (TNFR) member that is predominantly expressed on terminally differentiated B cells and, upon binding to its ligands B cell activator of the TNF family (BAFF) and a proliferation inducing
Han-Wen Huang et al.
Proceedings of the National Academy of Sciences of the United States of America, 110(27), 10928-10933 (2013-06-19)
Glycosylation, an important posttranslational modification process, can modulate the structure and function of proteins, but its effect on the properties of plasma cells is largely unknown. In this study, we identified a panel of glycoproteins by click reaction with alkynyl
Liang Lin et al.
Leukemia, 35(3), 752-763 (2020-07-08)
Chimeric antigen receptor (CAR) T-cell therapy remains limited to select centers that can carefully monitor adverse events. To broaden use of CAR T cells in community clinics and in a frontline setting, we developed a novel CD8+ CAR T-cell product
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service